-

04:01:12 PM

AIM Stock News

AIM - AIM ImmunoTech Inc

09/21/22 8:45 AM

AMEX : AIM

conferencescovid-19

AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at 3:00 PM ET OCALA, Fla., Sept. 21, 2022 (GLOBE

RHEA-AI

neutral

09/19/22 8:05 AM

AMEX : AIM

AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

The Board of Directors of AIM ImmunoTech Inc., today announced that the Company has filed its Definitive Proxy Statement in connection with AIM' s upcoming 2022 Annual Meeting of Stockholders, to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders. Thank you for your investment and your trust in AIM ImmunoTech.

RHEA-AI

neutral

09/07/22 7:25 AM

AMEX : AIM

conferences

AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the

RHEA-AI

neutral

09/06/22 7:30 AM

AMEX : AIM

conferences

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the

RHEA-AI

neutral

08/30/22 7:30 AM

AMEX : AIM

clinical trial

AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen(R) (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma

AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the

RHEA-AI

neutral

08/18/22 9:05 AM

AMEX : AIM

clinical trial

AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc.

RHEA-AI

very positive

08/15/22 4:05 PM

AMEX : AIM

AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement regarding the outcome of a hearing in the Delaware Court of Chancery concerning a motion for a temporary restraining order sought by activist...

RHEA-AI

neutral

08/15/22 8:05 AM

AMEX : AIM

earnings

AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- On track to commence Phase 2 study for lead program evaluating Ampligen (R) (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 - Well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones - Capital position expected to fund company through end of

RHEA-AI

neutral

07/28/22 9:10 AM

AMEX : AIM

covid-19

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen(R) for the Treatment of Long COVID

AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM"

RHEA-AI

neutral

07/20/22 8:05 AM

AMEX : AIM

AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Ampligen(R) (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data provide further validation for advancing the development of Ampligen for the

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next